← All trials
NCT04502667
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 15, 2020
- Primary completion
- Feb 28, 2021
- Completion date
- Apr 30, 2021
- First posted
- Aug 6, 2020
- Last posted
- Aug 6, 2020
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Government of MexicoLead sponsor
- Government of MexicoCollaborator
- Government of MexicoOverall official - principal investigator
- Government of MexicoReponsible party - principal investigator
- Hospital General de México Dr. Eduardo LiceagaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.